Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an extra drug stop amoebic liver abscess from coming back?

NCT ID NCT07807150

Disease control Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether adding diloxanide furoate to the standard antibiotic metronidazole improves recovery from amoebic liver abscess, a serious infection of the liver caused by a parasite. About 220 adults with a new diagnosis will receive either the added drug or a placebo, alongside metronidazole. The goal is to see if the combination clears the parasite more completely, speeds up clinical cure, and prevents the abscess from recurring within 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diloxanide furoate, an antiparasitic drug, added to standard metronidazole treatment
What this could lead to
If adding diloxanide furoate works, it could reduce relapse and parasite spread after amoebic liver abscess treatment, improving recovery and lowering recurrence.
What could go wrong
This is a single trial, and the added drug may not improve outcomes beyond metronidazole alone. Possible side effects include gastrointestinal upset, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Age \>18 years 2. Male or Female 3. Patients with newly diagnosed amoebic liver abscess \- Exclusion Criteria: 1. Patients not able to take orally 2. Patients receiving antimicrobials for more than 72 hours before the enrolment in the study 3. History of hypersensitivity reactions to Metronidazole or Diloxanide furoate 4. Pregnancy 5. Patients on antiplatelets/anticoagulation within 4 weeks of presentation 6. Presentation with shock (SBP\<90 and/ or DBP\< 60 mmHg) 7. Patients with ARDS (SpO2 ≤92%, PaO2/Fio2\<300, requiring oxygen therapy) 8. Patients with renal dysfunction / CKD (Creatinine \>1.5mg/dl) 9. Patients with altered sensorium (GCS \<15) 10. Patients with known malignancy 11. Patients with HIV 12. Not willing for informed consent -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amoebic liver abscess are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Liver Abscess liver abscess (disease) Liver Abscess, Amebic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amoebic liver abscess Liver abscess

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Chandigarh, Chandigarh, 160012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.